GSK and Spero Therapeutics Secure Historic Utebzi FDA Approval for Adults with Complicated Urinary Tract Infections
The historic Utebzi FDA approval introduces the first and only oral carbapenem antibiotic for adult patients suffering from complicated urinary tract infections (cUTIs), offering an effective outpatient treatment pathway to combat multidrug-resistant pathogens.
Novo Nordisk Cyber Attack: Threat Group Demands $25 Million Ransom Following Massive Data Breach
Following a rejected $25 million extortion attempt, a cybercriminal group claims to have stolen 1.3 terabytes of sensitive data in a sophisticated Novo Nordisk cyber attack targeting proprietary drug files and AI systems.
Eli Lilly Announces Landmark Phase 3 Trial Results for Lilly Jaypirca CLL Treatment
Eli Lilly and Company announced results from its Phase 3 BRUIN CLL-322 trial, demonstrating that adding Jaypirca to a venetoclax time-limited regimen cuts the risk of disease progression or death by 45% in previously treated CLL/SLL patients.
FDA Announces AstraZeneca Truqap Prostate Cancer Approval for PTEN-Deficient Patients
US Food and Drug Administration has approved AstraZeneca’s Truqap (capivasertib) combination therapy as the first and only targeted treatment for adult patients suffering from PTEN-deficient mAPMN/S prostate cancer.
Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in earlier-line relapsed or refractory multiple myeloma.
Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected.
Danaher Acquisition of Masimo Completed in $9.9B Diagnostics Mega-Deal
Danaher Corporation has finalized its acquisition of Masimo Corporation, establishing the pulse oximetry and patient monitoring provider as a stand-alone operating company within its Diagnostics segment.
AstraZeneca Advances Oral GLP-1 RA Elecoglipron Asset into Phase III Programme Following Robust Phase IIb Results
AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to 11.8% weight loss and a 1.9% reduction in HbA1c.
Johnson & Johnson Firefly Bio Acquisition: JNJ Acquires Firelink DAC Platform for $1 Billion
Johnson & Johnson has announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash to secure its novel Firelinkâ„¢ degrader antibody conjugate platform.
Novo Nordisk Zenagamtide Drives Major HbA1c and Weight Reductions at ADA 2026
At the ADA 2026 Scientific Sessions, Novo Nordisk unveiled Phase 2 data for zenagamtide (amycretin), demonstrating exceptional blood sugar control and weight loss in type 2 diabetes.